{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:55:07Z","timestamp":1779353707505,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.mcpro.2021.100187","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T02:09:04Z","timestamp":1639620544000},"page":"100187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-3059","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weigang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-7651","authenticated-orcid":false,"given":"Tiannan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2021.100187_bib1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bbmt.2015.03.012","article-title":"Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: May we predict graft-versus-leukemia without graft-versus-host disease?","volume":"21","author":"Radujkovic","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.mcpro.2021.100187_bib2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J.\u00a0Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.mcpro.2021.100187_bib3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1200\/JCO.18.02037","article-title":"Clinical cancer advances 2019: Annual report on progress against cancer from the American Society of Clinical Oncology","volume":"37","author":"Pal","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2021.100187_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: A brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.mcpro.2021.100187_bib5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1159\/000495650","article-title":"Targeting P-glycoprotein: Nelfinavir reverses adriamycin resistance in K562\/ADR cells","volume":"51","author":"Liu","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.mcpro.2021.100187_bib6","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1002\/jcp.26087","article-title":"Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK\/ERK and Ca(2+) -mediated apoptosis pathways in MCF-7\/ADR and K562\/ADR","volume":"233","author":"Sun","year":"2018","journal-title":"J.\u00a0Cell Physiol."},{"key":"10.1016\/j.mcpro.2021.100187_bib7","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/sj.onc.1209293","article-title":"Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells","volume":"25","author":"De Oliveira","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.mcpro.2021.100187_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","article-title":"Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance","volume":"21","author":"Li","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2021.100187_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.223","article-title":"Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML","volume":"8","author":"Zhao","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mcpro.2021.100187_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib11","doi-asserted-by":"crossref","first-page":"100681","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.mcpro.2021.100187_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12234","article-title":"Do we need more drugs for chronic myeloid leukemia?","volume":"263","author":"Holyoake","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.mcpro.2021.100187_bib13","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38 Suppl 5","author":"Buchdunger","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mcpro.2021.100187_bib14","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2021.100187_bib15","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drup.2007.06.001","article-title":"Roots of imatinib resistance: A question of self-renewal?","volume":"10","author":"Burchert","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.mcpro.2021.100187_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1368-7646(03)00062-1","article-title":"Resistance to imatinib (glivec): Update on clinical mechanisms","volume":"6","author":"Weisberg","year":"2003","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.mcpro.2021.100187_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.mcpro.2021.100187_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-016-2999-1","article-title":"Molecular chess? Hallmarks of anti-cancer drug resistance","volume":"17","author":"Cree","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mcpro.2021.100187_bib20","doi-asserted-by":"crossref","first-page":"188310","DOI":"10.1016\/j.bbcan.2019.188310","article-title":"Mechanisms of acquired tumor drug resistance","volume":"1872","author":"Aleksakhina","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.mcpro.2021.100187_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature19949","article-title":"Mass-spectrometric exploration of proteome structure and function","volume":"537","author":"Aebersold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2021.100187_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13046-018-0843-y","article-title":"SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22\/IPO7\/HIF-1\u03b1 axis","volume":"37","author":"Monteleone","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib23","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1021\/pr100814y","article-title":"Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in K562 human chronic myeloid leukemia cells","volume":"9","author":"Xiong","year":"2010","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-5956-10-23","article-title":"A\u00a0comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line","volume":"10","author":"Corr\u00eaa","year":"2012","journal-title":"Proteome Sci."},{"key":"10.1016\/j.mcpro.2021.100187_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/pr0603708","article-title":"Comparative proteomic analysis of chronic myelogenous leukemia cells: Inside the mechanism of imatinib resistance","volume":"6","author":"Ferrari","year":"2007","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/epr.12.55","article-title":"Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid","volume":"9","author":"Gjertsen","year":"2012","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100187_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3892\/ijo.2020.5163","article-title":"Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib","volume":"58","author":"Hrdinova","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.mcpro.2021.100187_bib28","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.O111.016717","article-title":"Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis","volume":"11","author":"Gillet","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100187_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41467-017-00249-5","article-title":"Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry","volume":"8","author":"Collins","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2021.100187_bib30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/acs.jproteome.0c00381","article-title":"PulseDIA: Data-independent acquisition mass spectrometry using multi-injection pulsed gas-phase fractionation","volume":"20","author":"Cai","year":"2021","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nm.3807","article-title":"Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2021.100187_bib32","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1002\/pmic.201500161","article-title":"Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry","volume":"15","author":"Shao","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2021.100187_bib33","doi-asserted-by":"crossref","first-page":"1900276","DOI":"10.1002\/pmic.201900276","article-title":"Data-independent acquisition mass spectrometry-based proteomics and software tools: A glimpse in 2020","volume":"20","author":"Zhang","year":"2020","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2021.100187_bib34","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1074\/mcp.M114.044305","article-title":"Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues","volume":"14","author":"Bruderer","year":"2015","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100187_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2021.100187_bib36","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1038\/s41467-018-07454-w","article-title":"Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry","volume":"9","author":"Searle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2021.100187_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nbt.2841","article-title":"OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data","volume":"32","author":"Rost","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2021.100187_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.gpb.2019.11.008","article-title":"Dphl: A DIA pan-human protein mass spectrometry library for robust biomarker discovery","volume":"18","author":"Zhu","year":"2020","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.mcpro.2021.100187_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/bioinformatics\/btaa1088","article-title":"ProteomeExpert: A docker image-based web server for exploring, modeling, visualizing and mining quantitative proteomic datasets","volume":"37","author":"Zhu","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.mcpro.2021.100187_bib40","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.4236","article-title":"Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine","volume":"36","author":"Chi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2021.100187_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nprot.2015.015","article-title":"Building high-quality assay libraries for targeted analysis of SWATH MS data","volume":"10","author":"Schubert","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mcpro.2021.100187_bib42","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: An interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.mcpro.2021.100187_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.6026\/97320630002005","article-title":"Mfuzz: A software package for soft clustering of microarray data","volume":"2","author":"Kumar","year":"2007","journal-title":"Bioinformation"},{"key":"10.1016\/j.mcpro.2021.100187_bib44","article-title":"Biological pathway analysis by ArrayUnlock and ingenuity pathway analysis","volume":"3 Suppl 4","author":"Jimenez-Marin","year":"2009","journal-title":"BMC Proc."},{"key":"10.1016\/j.mcpro.2021.100187_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kramer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.mcpro.2021.100187_bib46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1142\/S0219720005001375","article-title":"Noise-robust soft clustering of gene expression time-course data","volume":"3","author":"Futschik","year":"2005","journal-title":"J.\u00a0Bioinform. Comput. Biol."},{"key":"10.1016\/j.mcpro.2021.100187_bib47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.biochem.75.103004.142539","article-title":"Energy converting NADH:quinone oxidoreductase (complex I)","volume":"75","author":"Brandt","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.mcpro.2021.100187_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1152\/physrev.00006.2014","article-title":"Electronic connection between the quinone and cytochrome C redox pools and its role in regulation of mitochondrial electron transport and redox signaling","volume":"95","author":"Sarewicz","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.mcpro.2021.100187_bib49","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2174\/092986709787846578","article-title":"Mitochondrial respiratory complex I: Structure, function and implication in human diseases","volume":"16","author":"Sharma","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.mcpro.2021.100187_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/321282","article-title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma","volume":"69","author":"Astuti","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mcpro.2021.100187_bib51","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphys.2017.00460","article-title":"Mitochondrial VDAC1: A key gatekeeper as potential therapeutic target","volume":"8","author":"Camara","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.mcpro.2021.100187_bib52","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4161\/cbt.9.12.12451","article-title":"Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target","volume":"9","author":"Mathupala","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.mcpro.2021.100187_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10863-008-9148-8","article-title":"Regulation of hexokinase binding to VDAC","volume":"40","author":"Pastorino","year":"2008","journal-title":"J.\u00a0Bioenerg. Biomembr."},{"key":"10.1016\/j.mcpro.2021.100187_bib54","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.febslet.2014.05.028","article-title":"Mitochondrial protein translocases for survival and wellbeing","volume":"588","author":"Sokol","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.mcpro.2021.100187_bib55","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1074\/mcp.M116.058131","article-title":"Novel entropically driven conformation-specific interactions with Tomm34 protein modulate Hsp70 protein folding and ATPase activities","volume":"15","author":"Durech","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100187_bib56","first-page":"381","article-title":"Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target","volume":"29","author":"Shimokawa","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.mcpro.2021.100187_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13048-019-0498-0","article-title":"Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage","volume":"12","author":"Muller","year":"2019","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-012-2249-4","article-title":"TOMM34 expression in early invasive breast cancer: A biomarker associated with poor outcome","volume":"136","author":"Aleskandarany","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mcpro.2021.100187_bib59","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1566524011313040005","article-title":"Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer","volume":"13","author":"Mat\u00e9s","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.mcpro.2021.100187_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2015.078","article-title":"alpha-Ketoglutarate: Physiological functions and applications","volume":"24","author":"Wu","year":"2016","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.mcpro.2021.100187_bib61","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2021.100187_bib62","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.mcpro.2021.100187_bib63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4161\/cbt.4.1.1434","article-title":"The thioredoxin reductase\/thioredoxin system: Novel redox targets for cancer therapy","volume":"4","author":"Biaglow","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.mcpro.2021.100187_bib64","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2021.100187_bib65","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/bjc.2015.146","article-title":"Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'","volume":"112","author":"Pisco","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2021.100187_bib66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.canlet.2015.05.004","article-title":"The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in\u00a0vitro","volume":"364","author":"Piskareva","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mcpro.2021.100187_bib67","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nbt.3685","article-title":"A\u00a0multicenter study benchmarks software tools for label-free proteome quantification","volume":"34","author":"Navarro","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2021.100187_bib68","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-14-2290","article-title":"SIRT1\/PGC1\u03b1-dependent increase in oxidative phosphorylation supports chemotherapy resistance of colon cancer","volume":"21","author":"Vellinga","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100187_bib69","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tibs.2010.07.003","article-title":"Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling","volume":"35","author":"Verdin","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.mcpro.2021.100187_bib70","doi-asserted-by":"crossref","first-page":"100643","DOI":"10.1016\/j.drup.2019.100643","article-title":"What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg","volume":"46","author":"Alexa-Stratulat","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.mcpro.2021.100187_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pharmthera.2015.05.003","article-title":"Metabolic consequences of oncogenic IDH mutations","volume":"152","author":"Parker","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mcpro.2021.100187_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.leu.2400538","article-title":"A\u00a0novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia","volume":"11","author":"Hedley","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2021.100187_bib73","doi-asserted-by":"crossref","first-page":"13679","DOI":"10.1073\/pnas.1712064115","article-title":"Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance","volume":"114","author":"Su","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947621001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947621001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:08:28Z","timestamp":1761527308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947621001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1535947621001596"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2021.100187","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.08.438976","asserted-by":"object"}]},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2021.100187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100187"}}